acamprosate vs buprenorphine/naloxone
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and buprenorphine/naloxone. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Suboxone
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Suboxone film contains buprenorphine and naloxone. It is used to treat opioid dependence as part of a complete treatment plan.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Suboxone film is used to treat opioid dependence. Opioid dependence means you are addicted to opioid drugs. This medicine should be used with counseling and support.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Buprenorphine is a partial opioid agonist, meaning it has some opioid effects. Naloxone is an opioid antagonist, which blocks the effects of opioids. Together, they help reduce cravings and withdrawal symptoms without causing a strong "high."
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Mouth numbness
- • Tongue pain
- • Mouth redness
- • Headache
- • Feeling sick to your stomach
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Feeling sick to your stomach 138
- Throwing up 92
- Reaction at the injection site 90
- Headache 79
- Problem with the medicine being substituted 73
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Buprenorphine can be abused, like other opioids. Taking Suboxone with other depressants like alcohol or benzodiazepines can cause serious breathing problems, coma, or death. Keep Suboxone out of the reach of children, as it can cause severe breathing problems and death if they take it. Using opioids for a long time during pregnancy can cause withdrawal symptoms in the newborn.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
If you are pregnant or plan to become pregnant, talk to your doctor. Using Suboxone during pregnancy can cause withdrawal symptoms in the baby after birth. Buprenorphine passes into breast milk, so talk to your doctor before breastfeeding.
How to Read This acamprosate vs buprenorphine/naloxone Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while buprenorphine/naloxone sits within the Partial Opioid Agonist / Antagonist class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while buprenorphine/naloxone has 472. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or buprenorphine/naloxone.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.